Objective: After approval of bevacizumab in Japan, post-marketing surveillance studies reported on safety. However, few reports have shown the efficacy of bevacizumab as used in daily practice. We evaluated the efficacy and safety of bevacizumab for metastatic colorectal cancer patients in daily practice. Methods: All unresectable metastatic colorectal cancer patients who began receiving bevacizumab in participating facilities from June 2007 to October 2008 were retrospectively analyzed for safety and efficacy. Adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events. Response Evaluation in Solid Tumors criteria, version 1.0, was used for the tumor response rate. Results: A total of 212 patients from 17 institutions were assessed. Grade 3 or higher adverse events related to bevacizumab included gastrointestinal perforation in 3, thrombosis in 7, hypertension in 30 and gastrointestinal bleeding in 2. Response rates were 62.5, 30.1 and 11.8% overall among patients receiving bevacizumab as first-, second-and third-line or greater therapy. Median progression-free survival was 14.4 [95% confidence interval (CI): 10.8 -18.1], 7.8 (95% CI: 6.5 -9.1) and 6.0 (95% CI: 4.6 -7.3) months, and median overall survival was 32.5 (95% CI: 24.6 -40.3), 16.4 (95% CI: 14.4 -18.5) and 11.8 (95% CI: 8.6 -15.0) months, respectively. Conclusions: The general cohort of patients in HGCSG0801 showed a similar efficacy and safety profile of bevacizumab as seen in clinical trials. Although the sample size was small and there were several study limitations, these results suggest that colorectal cancer patients in Japan might safely receive and benefit from bevacizumab in combination with chemotherapy in daily practice, as is seen in patients in other countries.
INTRODUCTION
Bevacizumab (Avastin; Genentech, South San Francisco, CA, USA) is a humanized monoclonal antibody that inhibits vascular endothelial growth factor. Bevacizumab shows antitumor activity by inhibiting angiogenesis and normalizing abnormal tumor vasculature (1, 2) . In some randomized, prospective trials, bevacizumab combined with chemotherapy considerably improved response rates, overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC) (3 -6) . However, not all of these endpoints were met in each study.
In the NO16966 study, a randomized prospective Phase III trial, the addition of bevacizumab to oxaliplatin-based chemotherapies resulted in a better median PFS than chemotherapy without bevacizumab [9.4 vs. 8 .0 months; hazard ratio, 0.83; 97.5% confidence interval (CI), 0.72 -0.95; P ¼ 0.0023] (4). In the PACCE study, a randomized Phase III trial, median PFS with oxaliplatin-based chemotherapy with bevacizumab was 11.1 months (5). These Phase III trials indicate that the median PFS of oxaliplatin-based chemotherapy with bevacizumab is 10 months. Bevacizumab with irinotecan-based chemotherapies also showed a good median PFS: 11.2 months in the BICC-C trial (6) and 11.7 months in the PACCE study (5) .
The BRiTE (7) and First BEAT study (8) , prospective observational trials in general daily practice patients treated with bevacizumab, reported an efficacy equal to that seen in randomized prospective Phase III trials. In the BRiTE study, the median PFS of FOLFOX [oxaliplatin and infused 5-fluorouracil (5-FU) and leucovorin (5-FU/LU)] or FOLFIRI (irinotecan and 5-FU/LU) with bevacizumab was 10 and 10.9 months, respectively (7) . In First BEAT, the median PFS of FOLFOX or FOLFIRI with bevacizumab was 11.3 and 11.6 months, respectively (8) .
Hypertension, bleeding, thrombosis and gastrointestinal (GI) perforation are well-known adverse events induced by bevacizumab. These events were noted in a Japanese postmarketing surveillance study (9) , although their frequency was lower than that in the BRiTE (7) and First BEAT (8) observational cohort studies. This discrepancy may have resulted partly from a less vigorous collection of adverse events used in simple post-marketing surveillance compared with observational cohort clinical trials, which may lead to a lower incidence of adverse events. Thus, results of postmarketing surveillance studies must be viewed with caution. In addition, there are few reports regarding the efficacy of bevacizumab used concomitantly with chemotherapy in daily practice in Japan.
We report the safety and efficacy of bevacizumab plus chemotherapy in a daily practice cohort drawn from patients in 17 institutions in cooperation with the Hokkaido Gastrointestinal Chemotherapy Study Group (HGCSG). Other than histologic confirmation, no other criteria for unresectable disease were provided. All patients who received bevacizumab, as identified by the pharmacies at these facilities, were enrolled (i.e. there were no exclusion criteria). We sent case-report forms to investigators, who provided the reports.
PATIENTS AND METHODS

PATIENTS
TREATMENTS
Eligible patients received bevacizumab combination chemotherapy with fluoropyrimidine alone or fluoropyrimidine plus oxaliplatin or irinotecan. Each treatment regimen was chosen at the clinician's discretion. The dose of bevacizumab was 5 mg/kg every 2 weeks in almost all cases; 10 mg/kg was used in some non-first-line chemotherapy regimens. Bevacizumab was administered intravenously over 30 -90 min.
ASSESSMENTS
Baseline data included medical history, such as hypertension, thromboembolic disease and duodenal or gastric ulcers. Assessment of adverse events was made at the investigator's discretion. The National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0, was used to assess adverse events.
Efficacy was assessed using OS, which was defined as the time from start of first bevacizumab administration to death, and PFS, which was defined as no progression at the time of survival investigation. Patients who underwent changes in the treatment regimen without evidence of progression were censored. The Response Evaluation in Solid Tumors (RECIST) criteria, version 1.0, was used to assess tumor response. In one-third of patients, each investigator evaluated tumor response by computed tomography (CT) scan or other images in accordance with RECIST, ver.1.0, and made clinical research forms of this study. For the remaining two-thirds of patients, a central reviewer for HGCSG went to each institution to evaluate tumor response by CT scan.
This study design and protocol were approved by the institutional review board of Hokkaido University Hospital and all other institutions. Because this was a retrospective cohort study, informed consent was not obtained. We announced on a website (www.hgcsg.com) about this research.
STATISTICS
Adverse events were assessed using standard frequency tables. OS and PFS were recorded based on the investigator's assessment. Tumor response was assessed every 2 months in almost all patients. The Kaplan -Meier method was used to determine PFS and OS. Log-rank test was used to compare each regimen in terms of PFS and OS. All statistical tests were performed using SPSS (Chicago, IL, USA).
RESULTS
PATIENT CHARACTERISTICS
A total of 212 patients were enrolled. Baseline characteristics of patients are shown in Table 1 . Patients were divided into three groups according to their treatment line: first line (n ¼ 88) was defined as patients who had received no prior chemotherapy except for adjuvant chemotherapy over the past 6 months; second line (n ¼ 73) was defined as patients who had received one prior chemotherapy regimen and third-line or greater therapy (n ¼ 51) was defined as patients who had received two prior chemotherapy regimens (n ¼ 38) or more than three prior chemotherapy regimens (n ¼ 13). Reasons for changes in regimens included progressive disease, toxicity and other reasons. In terms of previous regimens, among secondline patients, 44 received an oxaliplatin-combined regimen, 16 received irinotecan and 13 received 5-FU/LV. Bevacizumab was used in eight patients in prior chemotherapy. In terms of previous regimens among third-line or greater patients, 27 patients received irinotecan, oxaliplatin and 5-FU in prior chemotherapies, 23 patients received only oxaliplatin and 5-FU and 1 patient received only irinotecan and 5-FU. Bevacizumab was used in 12 patients in prior chemotherapies.
The median age of all patients was 61 years (range: 32 -82 years). One hundred and forty-three patients had colon cancer and 69 had rectal cancer. Most patients showed Eastern Cooperative Oncology Group Performance Status of 0 or 1. In terms of metastatic sites, 16 of 51 patients (31%) receiving third-line or greater therapy had peritoneal metastases. Baseline characteristics were similar among patients receiving first-, second-and third-line or greater therapy.
Forty patients (19%) had hypertension at baseline and 16 (8%) had a history of gastric or duodenal ulcer. Most patients received combination therapy that contained 5-FU and either irinotecan or oxaliplatin; the most common regimens were FOLFOX6 (45%) and FOLFIRI (34%). Irinotecan and S-1 (IRIS), a combination of IRIS, an orally active prodrug of 5-FU that contains tegafur (which is continuously metabolized to 5-FU) blended with two modulators, gimeracil and potassium oxonate, which had been tested in a Phase II study in our group, was administered to 29 patients (14%).
SAFETY
Adverse events related to bevacizumab are shown in Table 2 . Severe adverse events occurred in some patients. One case of Grade 5 thrombosis of the pulmonary artery possibly related to bevacizumab was reported. There were no other Grade 5 adverse events. Four Grade 4 adverse events were reported, including ischemic colitis due to thrombosis of the superior mesenteric artery, a postoperative wound dehiscence of the abdomen that required another surgery to address the wound-healing complication and one GI perforation of the duodenum and rectum each. A GI perforation 
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Bevacizumab in daily practice: HGCSG0801 regarded as a characteristic adverse event of bevacizumab occurred in three patients (two in the rectum and one in the duodenum). All three patients underwent prior primary resection. One rectal perforation was related to metastasis of the peritoneum but had no relationship to the primary tumor. Thirty-eight Grade 3 adverse events were reported; five of these patients had Grade 3 thrombosis, including two with venous thrombosis related to the central venous catheter reservoir. Hypertension was observed in 120 of 212 patients (57%, all grade); 30 patients experienced Grade 3 hypertension that required intensive treatment.
About 30% of patients experienced some bleeding (any grade); most of these were epistaxis (49 patients). Fourteen cases of lower GI bleeding were reported, including two cases of Grade 3 bleeding that required a blood transfusion. Only four cases of lower GI bleeding from the primary site occurred.
EFFICACY
FIRST-LINE THERAPY
Eighty-eight patients, including 52 who received a FOLFOX regimen, 29 who received IRIS and 7 who received FOLFIRI, were treated with first-line therapy. For all 88 patients, median PFS (55 events) was 14.4 months (95% CI: 10.8 -18.1 months). Median PFS was 13.0 months (95% CI: 10.5 -15.5 months) for FOLFOX, 17.0 months (95% CI: 15.8 -18.2) for IRIS and 6.9 months (95% CI: 3.4 -10.5 months) for FOLFIRI (Fig. 1A) . Median OS (29 events) was 32.5 months (95% CI: 24.6 -40.3 months) overall, 28.1 months (95% CI: 23.8 -32.4 months) for FOLFOX, 17.6 months for FOLFIRI (95% CI was not calculated because of the small sample size) and not reached for IRIS (Fig. 1B) . The tumor response rate was 62.5% overall, with 5 patients showing a complete response (CR) and 50 showing a partial response (PR); 28 patients showed stable disease (SD). Tumor response rates by regimen were 53.8% for FOLFOX, 75.9% for IRIS and 71.4% for FOLFIRI (Table 3 ). CTCAE, Common Terminology Criteria for Adverse Events; GI, gastrointestinal; NOS, not otherwise specified. (Table 3) .
SECOND-LINE THERAPY
THIRD-LINE OR GREATER THERAPY
Fifty-one patients received third-line or greater therapy. Median OS (35 events) was 11.8 months (95% CI: 8.6 -15.0 months) and median PFS (48 events) was 6.0 months (95% CI: 4.6 -7.3 months); the overall response rate was 11.8% for all. Among these patients, 27 had experienced progression after receiving both oxaliplatin and irinotecan in past treatments. Among these 27 patients, the median PFS (26 events) was 5.6 months (95% CI: 3.7 -7.5 months), median OS (20 events) was 11.8 months (95% CI: 8.5 -15.1 months) and the response rate was 7.4%.
METASTASECTOMY
Hepatic metastasectomy was performed in 12 patients (5.7% of all patients; 11.3% of patients receiving first-line therapy). Pulmonary metastasectomy was performed in two patients. Three patients underwent radiofrequency ablation for liver metastasis, and two patients underwent surgery of another kind. The probability of 1-and 2-year survival was 100 and 80% in 10 patients who underwent hepatic metastasectomy, and 88.5 and 36.8%, respectively, in the other 78 patients who had received first-line chemotherapy. Median OS in the 10 patients who underwent hepatic metastasectomy was not reached.
DISCUSSION
This retrospective research was conducted to evaluate the safety and efficacy of bevacizumab in daily practice as opposed to a prospective randomized clinical trial. In western countries, similar observational cohort studies such as BRiTE (7) and BEAT (8) showed the safety and efficacy of bevacizumab only when used as a first-line therapy. The goal of this study was to evaluate adverse events and efficacy of bevacizumab when used as first-, second-or third-line or greater treatment in daily clinical practice in Japan.
The high frequency of hypertension in this study was noteworthy. Hypertension occurred in 120 of 212 patients (57%, all grade), and Grade 3 hypertension occurred in 30 patients (14.2%). In BRiTE, hypertension (all grade) was reported in 20.7% of patients (7). In BEAT, all grade hypertension was reported in 29.9%, and 5.3% experienced Grade 3 (8). In BEAT, Van Cutsem et al. (8) considered that the reduced incidence of hypertension was the result of increasing awareness of the toxicity profile of bevacizumab and better patient selection and earlier intervention. A Japanese post-marketing surveillance study reported a remarkably lower incidence of hypertension (all grade, 13%) (9) . In that report, the lower incidence of hypertension may have resulted partly from a less vigorous collection of hypertension. In other words, because it was not a strict observational cohort study, but a post-marketing surveillance study, not all adverse events, and especially non-critical adverse events such as slight bleeding or asymptomatic hypertension, were reported. In addition, in terms of grading of hypertension as an adverse event in CTCAE, ver.3.0, the start of antihypertensive therapy usually represents Grade 2 hypertension. Although the administration of more than two antihypertensive drugs does not always represent Grade 3 hypertension, especially when these drugs are used as prophylactic therapy, in our study, most of the local investigators automatically regarded the administration of two antihypertensive drugs as Grade 3 hypertension. This might explain the high frequency of Grade 3 hypertension in our study.
In previous post-marketing studies, if investigators did not assess hypertension and did not start a hypertensive drug, the grade of hypertension would be underestimated. In contrast, in our research, many investigators intensively started antihypertensive therapy early on and carefully assessed hypertension. This may have lead to the greater incidence of hypertension noted in this study. However, the fact that only one patient discontinued bevacizumab because of hypertension showed good management of this adverse effect in our study. The reason for the high incidence of baseline hypertension was unclear. 494 Bevacizumab in daily practice: HGCSG0801
The incidence of bleeding events in our study was similar to past reports (7, 8) . Fourteen cases of lower GI bleeding were reported. Furthermore, 87% of patients underwent primary resection. There were only four cases of lower GI bleeding from the primary site, and these cases were not severe. Primary resection is needed for patients with severe stenosis and bleeding to improve quality of life. However, prior surgery sometimes leads to a delay in the start of chemotherapy, especially bevacizumab, because of complications of surgery or progression of systemic disease. The timing and need for primary resection should be carefully discussed in each case.
Wound-healing complications were seen in 2% of patients and were mostly mild except for one case that experienced postoperative wound dehiscence of the abdomen and required another operation. Thrombosis was reported in 5% (all grade) and 3% (Grade 3) of patients, including one case of Grade 5 thrombosis of the pulmonary artery. Five of 11 patients with thrombosis discontinued bevacizumab. This incidence was higher than that seen in BEAT (8) and BRiTE (7). The thrombosis cases in this study included five cases of asymptomatic venous thrombosis related to the central venous catheter device. The relationship between thrombosis and these devices is unclear because most patients had this device. As with hypertension, awareness of thrombosis as an adverse event may lead to increased detection of asymptomatic thrombosis.
The incidence of GI perforation in this study was similar to past reports (7 -9). All three patients with GI perforation underwent prior primary resection. One case of rectal perforation was related to metastasis of the peritoneum but not to the primary tumor itself. Although some studies have not reported a relationship between age and GI perforation (9 -11) , there was significant relationship between age and GI perforation in our study ( patients aged 65 and .65 were compared, P ¼ 0.047 by Fisher's exact test). However, our whole sample size and the incidence of GI perforation were too small to analyze statistically.
Our research included patients receiving first-, secondand third-line or greater therapy, differentiating it from BEAT and BRiTE, which consisted of first-line patients only. Among patients in our study receiving first-line therapy, the median PFS was 14.4 months (95% CI: 10.8 -18.1 months), which is similar to rates seen with first-line therapy in randomized trials (9.2 -11.4 months) (3 -6,12,13) , BEAT (10.8 months) (8) and BRiTE (9.9 months) (7). However, our study was retrospective; so the interval of evaluation of tumor response that was used to determine disease progression was not defined. In addition, 29 of 88 patients who received first-line therapy in this study may represent a better population, as they had also enrolled in our Phase II study of IRIS plus bevacizumab. The median OS of 88 patients receiving first-line therapy was 32.5 months (95% CI: 24.6 -40.3 months) in this study, which is also similar to values reported in randomized trials (16.6 -28 .0 months) (3 -6,12,13), BEAT (22.7 months) (8) and BRiTE (22.9 months) (7) . These data support the benefit of bevacizumab for survival of patients in daily practice.
For second-line therapy, the median PFS was 7.8 months (95% CI: 6.5 -9.1 months). This finding is similar to the E3200 study (7.3 months) (14) , and some small retrospective reports in Japan and Turkey (6.0 -10.2 months) (15 -17) . These data also suggest the efficacy of bevacizumab as second-line therapy in daily practice.
In third-line or greater therapy, the median PFS of 51 patients was 6.0 months (95% CI: 4.6 -7.3 months). Among these 51 patients, 27 patients who had failed both irinotecan and oxaliplatin, including 3 patients who received past bevacizumab in prior treatments, showed a median PFS of 5.6 months (95% CI: 3.7 -7.5 months). TRC-0301 consisted of patients who had failed both irinotecan and oxaliplatin in prior treatments and showed a response rate of only 1% but a median PFS of 3.5 months (18) . Another pilot study which included patients with the same background showed a similar median PFS of 3.9 months (19) ( Table 4) . Other retrospective studies support the possible efficacy of bevacizumab with these patients (20, 21) . Although there is no evidence supporting the use of bevacizumab for third-line or greater therapy, these results suggest the possibility of the usefulness of re-administration of cytotoxic chemotherapy with bevacizumab as salvage treatment in selected patients. As bevacizumab combination chemotherapy becomes standard in first-or second-line treatment regimens, additional data regarding its use in later treatment may become available. However, the sample size of this current study, along with other biases, does not allow firm conclusions to be made.
Cetuximab (ERBITUX; ImClone Systems Inc., New York, NY, USA, and Bristol-Myers Squibb Co, Princeton, NJ, USA) is a chimeric monoclonal immunoglobulin 1 that binds to the epidermal growth factor receptor used in postbevacizumab chemotherapy. Thirty of 88 patients (34.1%) receiving first-line therapy, 33 of 73 patients (45.2%) patients receiving second-line therapy and 16 of 51 patients (31.4%) receiving third-line therapy received cetuximab in post-bevacizumab chemotherapy. The use of cetuximab might partly contribute to good OS in this study. This study included 29 patients (14%) who received IRIS as part of a Phase II study, not as part of daily practice. Thus, it is possible that we should not have included these patients in our analysis. However, IRIS has been proved to be noninferior to FOLFIRI in terms of efficacy and safety in secondline chemotherapy (22) . Furthermore, although IRIS had not become a standard chemotherapy when this study was conducted, we consider that the definition of 'daily practice patients' includes all patients visiting our hospital, including those participating in clinical trials. Thus, we considered IRIS patients as 'daily practice patients' in this study.
There are several important limitations to this study. First, the sample size of this study was too small to evaluate the safety and efficacy of bevacizumab. Second, this is not a prospective study, but a retrospective cohort study, which has many biases, including the inability to determine cause and effect, the difference of treatment regimen and schedule in each patient. Third, although all patients who received bevacizumab in the specified facilities were enrolled, the possibility of selection bias still exists. This is because this study was started soon after bevacizumab was approved in Japan. Fourth, all patients in this study showed good performance status, and thus may have been at a lower risk of experiencing adverse events associated with chemotherapy or bevacizumab, such as GI perforations, thrombosis, severe bleeding and hypertension. Finally, the interval between tumor assessment and patient visits was not defined because this study was retrospective in design. This factor could have caused our PFS to be overestimated. However, these factors are less likely to influence OS findings. Thus, we consider that the OS shown in this study may reflect a true survival benefit of bevacizumab in daily practice.
In conclusion, our study of general cohort patients showed a similar efficacy and safety profile of bevacizumab to some prospective randomized clinical trials and other observational studies. Although the sample size was small and there were several study limitations, these results suggest that colorectal cancer patients in Japan might safely receive and benefit from bevacizumab, in combination with chemotherapy in daily practice, as is seen in patients in other countries.
